| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | HSD17; EDHB17; EDH17B2; SDR28C1 |
| WB Predicted band size | 35 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human HSD17B1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇与HSD17B1抗体相关的虚构参考文献示例(基于常见研究方向模拟，非真实文献)：
---
1. **文献名称**：*Immunohistochemical analysis of HSD17B1 expression in breast cancer tissues*
**作者**：Zhang L, et al.
**期刊**：Oncology Reports, 2020
**摘要**：本研究利用特异性HSD17B1抗体，通过免疫组化技术检测了乳腺癌组织中HSD17B1的蛋白表达水平。结果显示，HSD17B1在雌激素受体阳性肿瘤中显著高表达，且与患者预后不良相关，提示其可能作为乳腺癌治疗的潜在靶点。
---
2. **文献名称**：*Development and validation of a monoclonal antibody for HSD17B1 enzyme activity detection*
**作者**：Smith JR, et al.
**期刊**：Journal of Molecular Endocrinology, 2018
**摘要**：研究团队开发了一种高特异性HSD17B1单克隆抗体，并通过Western blot和免疫荧光验证其灵敏度。该抗体成功用于检测卵巢颗粒细胞中HSD17B1的亚细胞定位，证实其在类固醇合成中的关键作用。
---
3. **文献名称**：*HSD17B1 expression in endometriosis: A comparative study using antibody-based proteomics*
**作者**：Tanaka K, et al.
**期刊**：Fertility and Sterility, 2019
**摘要**：通过抗体介导的蛋白质组学分析，本研究揭示了HSD17B1在子宫内膜异位症患者组织中的异常表达模式。研究强调HSD17B1抗体在区分病变与正常子宫内膜中的诊断价值。
---
**注**：以上文献为模拟示例，实际引用需通过PubMed、Web of Science等平台检索真实文献(可搜索关键词：HSD17B1 antibody, 17β-HSD1 immunohistochemistry)。如需进一步协助定位真实文献，请提供更多研究背景或目标。
The HSD17B1 antibody is a research tool designed to detect and study 17β-hydroxysteroid dehydrogenase type 1 (HSD17B1), an enzyme critical in steroid hormone metabolism. HSD17B1 belongs to the 17β-HSD enzyme family, which regulates the interconversion of less active and more potent sex steroids. Specifically, HSD17B1 catalyzes the reduction of estrone (E1) to estradiol (E2), the most biologically active estrogen, thereby influencing estrogen-dependent physiological and pathological processes. This enzyme is predominantly expressed in reproductive tissues (e.g., ovaries, placenta) and hormone-responsive cancers (e.g., breast, ovarian), making it a focus in studies of endocrine disorders and malignancies.
HSD17B1 antibodies are widely used in immunohistochemistry (IHC), western blotting (WB), and immunofluorescence (IF) to evaluate protein expression, localization, and regulation in tissues or cell lines. Research highlights its role in hormone-dependent cancer progression, as elevated HSD17B1 levels correlate with increased local estrogen production, tumor growth, and poor prognosis. Additionally, these antibodies aid in exploring HSD17B1's involvement in conditions like endometriosis and polycystic ovary syndrome (PCOS). Recent studies also investigate HSD17B1 inhibitors as potential therapeutics for estrogen-driven cancers. As a biomarker, HSD17B1 expression analysis helps stratify patients for targeted therapies, underscoring its translational relevance. The antibody's specificity and validation in diverse experimental models remain crucial for advancing both basic and clinical research in endocrinology and oncology.
×
